BridgeMD
New treatment option for Solid Cancer
Official title A Study of HS-20124 in Patients with Advanced Solid Tumors
ClinicalTrials.gov ID: NCT06763159
What this study is testing
What is HS-20124 (Phase Ia：Dose escalation )?
HS-20124 (Phase Ia：Dose escalation ) is an investigational medicine, being studied as a potential treatment for solid cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- HS-20124 is a novel DAR-8 antibody-drug conjugate （ADC） targeting CDH6. In preclinical studies, it inhibited tumor cell growth expressing CDH6 in vitro and in vivo.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- At least age of 18 years at screening;
- Histologically or cytologically confirmed, locally advanced or metastatic solid tumors for which standard treatment either does not exist or has...
- At least one extra-cranial measurable lesion according to RECIST 1
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1
- Life expectancy \>= 12 weeks
You likely can't join if
- 1.Treatment with any of the following:
- Previous or current treatment with CDH6 targeted therapy
- Any cytotoxic chemotherapy and small molecule targeted anticancer drugs within 21 days or five half-livesprior to the first scheduled dose of HS-20124
- Prior treatment with a monoclonal antibody or investigational agents within 28 days prior to the first scheduled dose of HS-20124
- Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or...
- Major surgery within 4 weeks prior to the first scheduled dose of HS-20124 2. people with previous or concurrent malignancies 3. Inadequate bone...
See the full eligibility criteria
- At least age of 18 years at screening;
- Histologically or cytologically confirmed, locally advanced or metastatic solid tumors for which standard treatment either does not exist or has proven ineffective or unavailable or intolerable
- At least one extra-cranial measurable lesion according to RECIST 1
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1
- Life expectancy \>= 12 weeks
- Men or women should be using adequate contraceptive measures throughout the study;
- Females people must not be pregnant at screening or have evidence of non-childbearing potential
- Signed and dated Informed Consent Form
- 1.Treatment with any of the following:
- Previous or current treatment with CDH6 targeted therapy
- Any cytotoxic chemotherapy and small molecule targeted anticancer drugs within 21 days or five half-livesprior to the first scheduled dose of HS-20124
- Prior treatment with a monoclonal antibody or investigational agents within 28 days prior to the first scheduled dose of HS-20124
- Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled...
- Major surgery within 4 weeks prior to the first scheduled dose of HS-20124 2. people with previous or concurrent malignancies 3. Inadequate bone marrow reserve or organ dysfunction 4. Evidence of cardiovascular risk 5...
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.